Talus Bio tacks on $11M to target hard-to-reach transcription factors

Written By REQ

Talus Bio tacks on $11M to target hard-to-reach transcription factors

Seattle-based Talus Bioscience has raised $11.2 million in an early fundraising round, money that will go toward advancing the biotech’s portfolio of preclinical cancer programs and help build out the biotech’s drug discovery platform.

California VC Two Bear Capital led the charge for the “seed+” round, with participation from WRF Capital, NFX, YC Continuity Fund, Funders Club VC and BoxOne Ventures.

Talus Bio is targeting a challenging transcription factor linked to prostate cancer, plus brachyury-driven cancers.

Read the full story from Fierce Biotech here:

https://www.fiercebiotech.com/biotech/talus-bio-tacks-11m-target-hard-reach-transcription-factors

REQ

REQ offers award-winning digital marketing solutions for the branded world. Browse our selection of case studies for globally recognized brands like eBay and Amazon.

https://req.co/
Next

Montara Therapeutics Lands $8M for Brain-Only Drug Development